Current management options for liposarcoma and challenges for the future
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current management options for liposarcoma and challenges for the future
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 14, Issue 3, Pages 297-306
Publisher
Informa UK Limited
Online
2014-01-08
DOI
10.1586/14737140.2014.869173
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New activities for the anti-tumor agent trabectedin: taking two birds with one stone
- (2015) Maurizio D’Incalci et al. Oncotarget
- Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study
- (2013) B. L. Samuels et al. ANNALS OF ONCOLOGY
- Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma
- (2013) Mark A. Dickson et al. JOURNAL OF CLINICAL ONCOLOGY
- Lymphocyte Composition and Distribution in Inflammatory, Well-differentiated Retroperitoneal Liposarcoma
- (2012) William W. Tseng et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy
- (2012) A. Italiano et al. ANNALS OF ONCOLOGY
- NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma
- (2012) Seth M. Pollack et al. CANCER
- Phase I study of nelfinavir in liposarcoma
- (2012) Janet Pan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial
- (2012) J. J. Luke et al. CLINICAL CANCER RESEARCH
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- MDM2 inhibition in liposarcoma: a step in the right direction
- (2012) Anastasia Constantinidou et al. LANCET ONCOLOGY
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
- (2012) Isabelle Ray-Coquard et al. LANCET ONCOLOGY
- Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival
- (2011) A. Italiano et al. ANNALS OF ONCOLOGY
- Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
- (2011) A. Gronchi et al. ANNALS OF ONCOLOGY
- Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas
- (2011) Margaret von Mehren et al. CANCER
- Pleomorphic liposarcoma
- (2011) Markus P. Ghadimi et al. CANCER
- Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma
- (2011) Aimee M Crago et al. CURRENT OPINION IN ONCOLOGY
- The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis. An analysis of 104 tumors
- (2011) Caroline Louis-Brennetot et al. GENES CHROMOSOMES & CANCER
- Predicting Survival for Well-Differentiated Liposarcoma: The Importance of Tumor Location
- (2011) Caitlin A. Smith et al. JOURNAL OF SURGICAL RESEARCH
- Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
- (2011) Patrick Schöffski et al. LANCET ONCOLOGY
- Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing
- (2011) Françoise Ducimetière et al. PLoS One
- Genomic Investigation of Dedifferentiated Liposarcoma Suggests a Role for Therapeutic Targeting of the Tumor Epigenome
- (2011) P. S. Meltzer et al. Cancer Discovery
- Frequent Alterations and Epigenetic Silencing of Differentiation Pathway Genes in Structurally Rearranged Liposarcomas
- (2011) B. S. Taylor et al. Cancer Discovery
- Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: Leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma
- (2010) S. Tariq Mahmood et al. INTERNATIONAL JOURNAL OF CANCER
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
- (2010) Jordi Barretina et al. NATURE GENETICS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy
- (2009) Hyo Song Kim et al. BMC CANCER
- Clinical and Biological Significance of CDK4 Amplification in Well-Differentiated and Dedifferentiated Liposarcomas
- (2009) A. Italiano et al. CLINICAL CANCER RESEARCH
- Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
- (2009) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
- (2009) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Cell cycle kinases as therapeutic targets for cancer
- (2009) Silvia Lapenna et al. NATURE REVIEWS DRUG DISCOVERY
- Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma
- (2008) Vasilios Karavasilis et al. CANCER
- A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma
- (2008) Nabeel Pervaiz et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started